Head and neck squamous cell carcinoma (HNSCC) ranks as one of the most common cancers globally, with over 650,000 new cases ...

A research team from Oregon Health & Science University and Thayer School of Engineering at Dartmouth has developed an ...

Head and neck squamous cell carcinoma (HNSCC) ranks as one of the most common cancers globally, with over 650,000 new cases reported each year.

A study developed a new technique to accurately analyse the properties of cancer cells and the surrounding tissue at the ...

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant ...

An international team has developed a new imaging method that analyzes cancer cells and their surrounding tissue at a ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

We wanted to create a monitoring tool that helps clinicians understand what is going on in the patient at a precise level, ...

Results of a study recently published in the journal JCO Precision Oncology show that in the clinical trial context, combined ...

The trial will enrol patients with mCRC who are microsatellite stable (MSS), wild type (WT) RAS, WT BRAF, and human epidermal ...

The Food and Drug Administration gave the green light to a phase 1/2 trial of KSQ-001EX for patients with melanoma, head and neck squamous cell carcinoma and non-small cell lung cancer. B42-001, a ...

TG4050 has demonstrated its potential to prime an adaptive immune response against tumour antigens and prevent relapse in patients with locally advanced resected head and neck squamous cell carcinoma.